// App-Quantinova.ai

4068 : Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Charalampia Kyriakou

Principal Investigators

  • John Ashcroft

  • Brooke Ryder-Smith

  • Igor W. Blau

  • Miguel T. Hernandez

  • Jo Caers

  • Gerard Bos

  • Maria Asuncion Echeveste

  • Christian Berthou

  • Renato Zambello

  • Elisabeth Kuenburg

  • Barbara Rosettani

Medical Centers

  • Department of Medicine, Hematology and Clinical Immunology Section, University of Padua and Venetian Institute of Molecular Medicine, Padua, Italy

  • Department of Internal Medicine, Academic Hospital Maastricht, Maastricht, Netherlands

  • Department of Haematology, Northwick Park Hospital, North West London NHS Trust, Harrow, United Kingdom

  • Servicio de Hematologia Clinica, Hospital Universitario de Canarias, Tenerife, Spain

  • Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France

  • Hematology Unit, Department of Oncology, Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy

  • Department of Internal Medicine III, Charite Campus Benjamin Franklin, Berlin, Germany

  • Department of Medical On- cology, CHU Liege, Liege, Belgium

  • Servicio de Hematologia, Hospital Universitario Donostia, San Sebastian, Spain

Locations

  • Italy

  • Netherlands

  • Spain

  • Germany

  • United Kingdom

  • France

  • Belgium

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Venous thrombosis

  • Peripheral neuropathy

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Thalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • observational

  • randomized

  • non interventional

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved